Literature DB >> 19689233

Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease.

John M Ringman1, Luis D Medina, Yaneth Rodriguez-Agudelo, Mireya Chavez, Po Lu, Jeffrey L Cummings.   

Abstract

The definition of mild cognitive impairment (MCI) as a precursor for Alzheimer's disease (AD) represented an important step forward in diagnosing the illness in its earliest stage. However, diagnoses based principally on cognitive performance have limitations in that there is variability between centers in which tests are employed and in how they are interpreted. Advances in our understanding of imaging and biochemical changes occurring early in the illness have improved our ability to diagnose AD in this early phase and diagnostic criteria for AD have been proposed recently based on such biomarkers. Persons inheriting autosomal dominant mutations causing familial AD (FAD) are essentially certain to develop the disease. In our studies of preclinical persons at-risk for inheriting FAD, we applied MCI diagnostic criteria to carriers of FAD mutations to ascertain the extent to which they identified persons in the earliest stages of the clinical illness. Our results indicate the relative prevalence of MCI subtypes varies considerably depending on the tests used to measure cognition. Furthermore, we found that cognitive complaints in such persons were less predictive of mutation status than were informants' reports of cognitive loss. The study of FAD provides an opportunity to test various criteria for early AD and these observations should be taken into consideration in future iterations of such diagnostic criteria.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689233      PMCID: PMC2887763          DOI: 10.2174/156720509788929336

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  41 in total

1.  Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases.

Authors:  C J Galton; K Patterson; J H Xuereb; J R Hodges
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

2.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

3.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

Authors:  Miroslaw Brys; Elizabeth Pirraglia; Kenneth Rich; Sindre Rolstad; Lisa Mosconi; Remigiusz Switalski; Lidia Glodzik-Sobanska; Susan De Santi; Ray Zinkowski; Pankaj Mehta; Domenico Pratico; Leslie A Saint Louis; Anders Wallin; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-09-24       Impact factor: 4.673

4.  Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI.

Authors:  Martha Storandt; Elizabeth A Grant; J Philip Miller; John C Morris
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

5.  Mild cognitive impairment: long-term course of four clinical subtypes.

Authors:  A Busse; A Hensel; U Gühne; M C Angermeyer; S G Riedel-Heller
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

6.  Biochemical markers in persons with preclinical familial Alzheimer disease.

Authors:  J M Ringman; S G Younkin; D Pratico; W Seltzer; G M Cole; D H Geschwind; Y Rodriguez-Agudelo; B Schaffer; J Fein; S Sokolow; E R Rosario; K H Gylys; A Varpetian; L D Medina; J L Cummings
Journal:  Neurology       Date:  2008-05-28       Impact factor: 9.910

Review 7.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Steven T Dekosky; Pascale Barberger-Gateau; Jeffrey Cummings; André Delacourte; Douglas Galasko; Serge Gauthier; Gregory Jicha; Kenichi Meguro; John O'brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Yaakov Stern; Pieter J Visser; Philip Scheltens
Journal:  Lancet Neurol       Date:  2007-08       Impact factor: 44.182

8.  Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations.

Authors:  John M Ringman; Joseph O'Neill; Daniel Geschwind; Luis Medina; Liana G Apostolova; Yaneth Rodriguez; Barbara Schaffer; Arousiak Varpetian; Benjamin Tseng; Freddy Ortiz; Jaime Fitten; Jeffrey L Cummings; George Bartzokis
Journal:  Brain       Date:  2007-05-23       Impact factor: 13.501

9.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.

Authors:  Sandip Ray; Markus Britschgi; Charles Herbert; Yoshiko Takeda-Uchimura; Adam Boxer; Kaj Blennow; Leah F Friedman; Douglas R Galasko; Marek Jutel; Anna Karydas; Jeffrey A Kaye; Jerzy Leszek; Bruce L Miller; Lennart Minthon; Joseph F Quinn; Gil D Rabinovici; William H Robinson; Marwan N Sabbagh; Yuen T So; D Larry Sparks; Massimo Tabaton; Jared Tinklenberg; Jerome A Yesavage; Robert Tibshirani; Tony Wyss-Coray
Journal:  Nat Med       Date:  2007-10-14       Impact factor: 53.440

10.  Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study.

Authors:  Basil H Ridha; Josephine Barnes; Jonathan W Bartlett; Alison Godbolt; Tracey Pepple; Martin N Rossor; Nick C Fox
Journal:  Lancet Neurol       Date:  2006-10       Impact factor: 44.182

View more
  11 in total

Review 1.  Potential predictors of hippocampal atrophy in Alzheimer's disease.

Authors:  Vikas Dhikav; Kuljeet Anand
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

2.  Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease.

Authors:  Liana G Apostolova; Kristy S Hwang; Luis D Medina; Amity E Green; Meredith N Braskie; Rebecca A Dutton; Jeffrey Lai; Daniel H Geschwind; Jeffrey L Cummings; Paul M Thompson; John M Ringman
Journal:  Dement Geriatr Cogn Disord       Date:  2011-09-23       Impact factor: 2.959

3.  Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task.

Authors:  John M Ringman; Luis D Medina; Meredith Braskie; Yaneth Rodriguez-Agudelo; Daniel H Geschwind; Miguel A Macias-Islas; Jeffrey L Cummings; Susan Bookheimer
Journal:  Cereb Cortex       Date:  2010-08-20       Impact factor: 5.357

4.  Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

Authors:  Jewell B Thomas; Matthew R Brier; Randall J Bateman; Abraham Z Snyder; Tammie L Benzinger; Chengjie Xiong; Marcus Raichle; David M Holtzman; Reisa A Sperling; Richard Mayeux; Bernardino Ghetti; John M Ringman; Stephen Salloway; Eric McDade; Martin N Rossor; Sebastien Ourselin; Peter R Schofield; Colin L Masters; Ralph N Martins; Michael W Weiner; Paul M Thompson; Nick C Fox; Robert A Koeppe; Clifford R Jack; Chester A Mathis; Angela Oliver; Tyler M Blazey; Krista Moulder; Virginia Buckles; Russ Hornbeck; Jasmeer Chhatwal; Aaron P Schultz; Alison M Goate; Anne M Fagan; Nigel J Cairns; Daniel S Marcus; John C Morris; Beau M Ances
Journal:  JAMA Neurol       Date:  2014-09       Impact factor: 18.302

5.  Reaction time and response inhibition in autosomal dominant Alzheimer's disease.

Authors:  Luis D Medina; Ellen Woo; Yaneth Rodriguez-Agudelo; Hector Chaparro Maldonado; Dahyun Yi; Giovanni Coppola; Yan Zhou; Helena C Chui; John M Ringman
Journal:  Brain Cogn       Date:  2020-12-10       Impact factor: 2.682

6.  The relationship between cognitive impairment and homocysteine in a B12 and folate deficient population in China: A cross-sectional study.

Authors:  HuaXing Meng; Yang Li; Wei Zhang; YaRong Zhao; XiaoYuan Niu; JunHong Guo
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

7.  Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer's disease.

Authors:  John Matthew Ringman; Whitney Pope; Noriko Salamon
Journal:  J Neurol       Date:  2010-01-03       Impact factor: 4.849

8.  Conformation-dependent oligomers in cerebrospinal fluid of presymptomatic familial Alzheimer's disease mutation carriers.

Authors:  John M Ringman; Jennifer L Tomic; Giovanni Coppola; David Elashoff; Karen H Gylys; Charles G Glabe
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-12-15

9.  Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer's Disease and Amnesic Mild Cognitive Impairment.

Authors:  Nobuyuki Kobayashi; Shunichiro Shinagawa; Tomoyuki Nagata; Kazuya Shimada; Nobuto Shibata; Tohru Ohnuma; Koji Kasanuki; Heii Arai; Hisashi Yamada; Kazuhiko Nakayama; Kazuhiro Kondo
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

10.  Kai Xin San ameliorates scopolamine-induced cognitive dysfunction.

Authors:  Yu-Min Xu; Xin-Chen Wang; Ting-Ting Xu; Hong-Ying Li; Shang-Yan Hei; Na-Chuan Luo; Hong Wang; Wei Zhao; Shu-Huan Fang; Yun-Bo Chen; Li Guan; Yong-Qi Fang; Shi-Jie Zhang; Qi Wang; Wei-Xiong Liang
Journal:  Neural Regen Res       Date:  2019-05       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.